$CLBT

Barter David (Chief Financial Officer) sold 41,734 shares of Cellebrite DI Ltd. (CLBT) at $16.38 ($0.68M total) on 2026-07-08.

Cellebrite DI Ltd. (Nasdaq: CLBT) said it expanded its exclusive partnership with SkySafe to combine SkySafe drone detection and airspace intelligence with Cellebrite’s digital forensics platform. The firms aim to link real-time and historical UAV flight data with mobile forensic evidence for investigations. Cellebrite noted its March 2026 acquisition of SCG Canada, Inc.

Hogan Thomas E. (Chief Executive Officer) sold 103,188 shares of Cellebrite DI Ltd. (CLBT) at $15.76 ($1.63M total) on 2026-07-02.

Analysts issued multiple rating and price-target changes across Wall Street. JPMorgan upgraded Openlane to overweight and raised its Dec 2026 PT to $38; UBS upgraded Ecolab to buy with a $325 PT; Barclays upgraded SanDisk to overweight. Micron’s PT was raised to $1,175 by Barclays. JPMorgan upgraded FedEx to overweight ahead of late-June earnings.

GEE DAVID NICHOLAS (Chief Marketing Officer) sold 2,243 shares of Cellebrite DI Ltd. (CLBT) at $13.10 on 2026-05-21 under a Rule 10b5-1 trading plan.

Cellebrite DI Ltd. (CLBT) filed a Form 144 revealing 31,728 Ordinary shares vested as Restricted Share Units under an S-8 registered plan on May 15, 2026. The filing also detailed recent sales by affiliate Marcus Jewell, including 4,613 shares for $65,221.36 on February 18, 2026, and 383 shares for $4,983.33 on May 12, 2026. This report provides transparency regarding potential future share sales and recent affiliate transactions.

Cellebrite DI Ltd. (CLBT) filed a Form 144, reporting a proposed resale of 1,045 vested Restricted Share Units under an S-8 registered plan with a vesting date of May 11, 2026. The filing also detailed recent open-market sales by Marcus Jewell in February 2026, involving 1,779, 13,276, and 4,613 ordinary shares. This is a routine notice for planned employee or affiliate dispositions and has a neutral impact on the market.

Cellebrite DI Ltd, a digital forensics specialist, is facing increasing pressure from privacy advocates, regulatory scrutiny, and competitive market changes, leading to a reevaluation of its growth narrative by investors. The company's core business, focused on extracting data from mobile devices for law enforcement, is challenged by tightening government budgets and the emergence of new competitors. This confluence of factors has led to slower-than-expected bookings growth and a lack of clear catalysts for a significant rebound in its stock performance.

JPMorgan Chase & Co. has reduced its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.2% in the third quarter, selling 183,531 shares but retaining 683,842 shares valued at approximately $12.67 million. Analyst ratings for Cellebrite are mixed but lean positive, with a consensus "Moderate Buy" and a target price of $22.50. The company reported strong Q results with revenue beating estimates, and its stock is currently trading near $15.19.

This article identifies top high-growth tech stocks in the US for January 2026, amidst a rebounding market. It highlights Cellebrite DI (CLBT), Roku (ROKU), and Circle Internet Group (CRCL) as standout options. The analysis covers their market capitalization, primary operations, revenue and earnings growth projections, and strategic developments.